Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.

Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S.

Psychopharmacology (Berl). 2014 Feb;231(3):533-42. doi: 10.1007/s00213-013-3261-z. Epub 2013 Sep 8.

PMID:
24013610
2.

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.

Eur Neuropsychopharmacol. 2014 Jun;24(6):846-55. doi: 10.1016/j.euroneuro.2014.02.001. Epub 2014 Feb 25.

PMID:
24636461
3.

Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.

Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, Ashrafi M, Hassanzadeh E, Akhondzadeh S.

Paediatr Drugs. 2013 Dec;15(6):505-14. doi: 10.1007/s40272-013-0036-2.

PMID:
23821414
4.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
5.

The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.

Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeionoddini A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S.

Hum Psychopharmacol. 2016 Mar;31(2):103-12. doi: 10.1002/hup.2517. Epub 2016 Feb 8.

PMID:
26856695
6.

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.

Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001.

PMID:
24201233
7.

L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.

Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S.

J Psychiatr Res. 2014 Dec;59:125-31. doi: 10.1016/j.jpsychires.2014.08.016. Epub 2014 Sep 6.

PMID:
25227564
8.

Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.

Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.

J Clin Psychopharmacol. 2013 Jun;33(3):336-42. doi: 10.1097/JCP.0b013e31828b50a7.

PMID:
23609382
9.

A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.

Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S.

Psychopharmacology (Berl). 2013 Aug;228(4):595-602. doi: 10.1007/s00213-013-3064-2. Epub 2013 Mar 21.

PMID:
23515583
10.

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.

J Psychiatr Res. 2013 Apr;47(4):472-8. doi: 10.1016/j.jpsychires.2013.01.011. Epub 2013 Jan 30.

PMID:
23375406
11.

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA.

Psychopharmacology (Berl). 2011 Feb;213(4):809-15. doi: 10.1007/s00213-010-2044-z. Epub 2010 Oct 15.

PMID:
20949350
12.

A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.

Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, Noorbala AA, Ahmadi-Abhari SA, Hajiazim M, Abbasi SH, Akhondzadeh S.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):726-32. Epub 2007 Nov 23.

PMID:
18096287
13.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
14.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
15.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
16.
17.

Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.

Rezaei F, Mesgarpour B, Jeddian A, Zeionoddini A, Mohammadinejad P, Salardini E, Shahriari M, Zeinoddini A, Akhondzadeh S.

Hum Psychopharmacol. 2017 Jul;32(4). doi: 10.1002/hup.2583. Epub 2017 Apr 18.

PMID:
28421639
18.

Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.

Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group.

J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551.

PMID:
25004184
19.

Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.

Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S.

Daru. 2014 Jul 10;22:55. doi: 10.1186/2008-2231-22-55.

20.

A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.

Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M, Akhondzadeh S.

Acta Med Iran. 2015;53(6):337-45.

Supplemental Content

Support Center